Johnson Health Tech Co. Ltd.

As of June 30, 2026, Johnson Health Tech Co. Ltd. carries a market capitalization of 38.08B, placing it among publicly traded companies globally. Its enterprise value stands at 51.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Johnson Health Tech Co. Ltd.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Johnson Health Tech Co. Ltd. has 303.39M shares outstanding.

As of June 30, 2026, Johnson Health Tech Co. Ltd. trades at a trailing price-to-earnings ratio of 11.35. The price-to-sales ratio is 0.67, and the price-to-book ratio stands at 2.78.

As of June 30, 2026, Johnson Health Tech Co. Ltd. trades at an EV/EBITDA multiple of 8.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.41 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Johnson Health Tech Co. Ltd. trades at an EV/FCF ratio of 15.27, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 51.90B versus a market cap of 38.08B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Johnson Health Tech Co. Ltd. maintains a current ratio of 1.26, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 125.43, indicating elevated leverage, while an interest coverage ratio of 15.75 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Johnson Health Tech Co. Ltd. posted a return on equity (ROE) of 27.92, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.78 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.49, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.16, useful for judging operating efficiency across full business cycles. The company generates approximately 46.14M in revenue per employee across its workforce of 1,224.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.06 indicates how many times Johnson Health Tech Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Johnson Health Tech Co. Ltd. recorded 1.26B in income tax expense. That works out to an effective tax rate of 27.26, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.61B, leaving 3.35B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Johnson Health Tech Co. Ltd.'s stock has declined approximately 18.95% over the past 52 weeks. The 50-day moving average sits at 126.54, while the 200-day moving average is 129.32.

Over the twelve months ended June 30, 2026, Johnson Health Tech Co. Ltd. generated 56.47B in revenue and converted that into 3.35B in net income, yielding earnings per share of 11.04. EBITDA reached 6.20B, while operating income came in at 4.64B.

As of June 30, 2026, Johnson Health Tech Co. Ltd. holds 3.40B in cash and equivalents against 17.21B in total debt, resulting in a net debt position of 10.93B. Total book value stands at 13.71B, with working capital of 6.44B providing operational flexibility.

Johnson Health Tech Co. Ltd. produced 4.82B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.70B in capital expenditures, free cash flow totaled 3.11B - equivalent to 10.26 per share.

Over the twelve months ended June 30, 2026, Johnson Health Tech Co. Ltd. posted a gross margin of 53.16, reflecting its pricing power and cost economics. The operating margin of 8.21 and net profit margin of 5.94 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Johnson Health Tech Co. Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 8.16, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.67, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Johnson Health Tech Co. Ltd. shareholders.

Johnson Health Tech Co. Ltd.'s most recent stock split took place on August 27, 2015 with a 200:201 split ratio.

As of June 30, 2026, Johnson Health Tech Co. Ltd. has an Altman Z-Score of 2.72, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.